Vertex Pharmaceuticals Incorporated
General ticker "VRTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $111.7B (TTM average)
Vertex Pharmaceuticals Incorporated follows the US Stock Market performance with the rate: 37.6%.
Estimated limits based on current volatility of 1.3%: low 474.94$, high 487.29$
Factors to consider:
- Earnings expected soon, date: 2026-08-03 amc
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Total employees count: 6100 (+13.0%) as of 2024
- US accounted for 60.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Clinical trial failure, Regulatory and compliance, Manufacturing risks, Pricing pressure
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [356.20$, 529.57$]
- 2026-12-31 to 2027-12-31 estimated range: [382.42$, 561.42$]
Financial Metrics affecting the VRTX estimates:
- Negative: with PPE of 24.9 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 34.77 > 18.65
- Positive: Return on assets ratio (scaled to [-100,100]) of 13.36 > 6.08
- Positive: Shareholder equity ratio, % of 72.79 > 63.79
- Positive: 0.30 < Operating cash flow per share per price, % of 3.09
- Negative: Industry earnings per price (median), % of -12.84 <= 0
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term VRTX quotes
Relationship graph
Long-term VRTX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $9,869.20MM | $11,020.10MM | $12,001.30MM |
| Operating Expenses | $6,037.20MM | $11,253.00MM | $7,828.00MM |
| Operating Income | $3,832.00MM | $-232.90MM | $4,173.30MM |
| Non-Operating Income | $547.80MM | $481.40MM | $469.90MM |
| Interest Expense | $44.10MM | $30.60MM | $13.30MM |
| R&D Expense | $3,162.90MM | $3,630.30MM | $3,909.50MM |
| Income(Loss) | $4,379.80MM | $248.50MM | $4,643.20MM |
| Taxes | $760.20MM | $784.10MM | $690.00MM |
| Net Income(Loss)* | $3,619.60MM | $-535.60MM | $3,953.20MM |
| Stockholders Equity | $17,580.40MM | $16,409.60MM | $18,665.80MM |
| Inventory | $738.80MM | $1,205.40MM | $1,686.80MM |
| Assets | $22,730.20MM | $22,533.20MM | $25,643.00MM |
| Operating Cash Flow | $3,537.30MM | $-492.60MM | $3,631.40MM |
| Capital expenditure | $258.40MM | $297.70MM | $437.60MM |
| Investing Cash Flow | $-3,141.70MM | $-3,770.00MM | $-945.40MM |
| Financing Cash Flow | $-562.20MM | $-1,494.90MM | $-2,261.30MM |
| Earnings Per Share** | $14.05 | $-2.08 | $15.46 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.